Skip to main content
. Author manuscript; available in PMC: 2024 Nov 4.
Published in final edited form as: Cancer Lett. 2024 Jun 7;597:217023. doi: 10.1016/j.canlet.2024.217023

Fig. 2. Breast CSCs are inhibited by the combination of TrkA and JAK2 inhibitors.

Fig. 2.

Mammosphere formation assay of HER2-positive SKBRM (A) or BT474-TtzmR (B) after treatment with vehicle, Entrectinib, Pacritinib, or combination. Representative mammosphere images for each cell line are shown. Scale bar represents 200 μm. CD44high/CD24low flow cytometry of SKBRM (C) and BT474-TtzmR (D) after treatment with vehicle, Entrectinib, Pacritinib, or combination. Representative flow cytometry plots are shown. Western blot analysis of SKBRM (E) and BT474-TtzmR (F) after treatment with vehicle, Entrectinib, Pacritinib, or combination. Densitometry values (normalized to β-actin) are displayed below each blot. ALDH activity in SKBRM (G) or BT474-TtzmR (H) after treatment with vehicle, Entrectinib, Pacritinib, or combination. Data of three to four experimental repeats are presented as mean ± SEM. One-way ANOVA with Tukey’s multiple comparison post hoc test was used to compare p values.